Nkarta Inc (NKTX) Stock Price, Quote & News

Company Profile

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic...

Industry: Biotechnology

Sector: Healthcare

Phone: 925 407 1049

Website: www.nkartatx.com

Address:

1150 Veterans Boulevard, South San Francisco, United States

OriginalTradeonrumor Sep. 4 at 5:49 PM

$NKTX gobble gobble chomp chomp !! Another solid day!

0 · Reply

theBigDollarski Sep. 4 at 1:14 PM

$NKTX we get any good news on the trials and this will instantly double

0 · Reply

LSOTradingDesk Sep. 3 at 11:24 PM

$NKTX it's goin in this last hour of aftermarket 🏁

0 · Reply

aletz Aug. 27 at 7:03 PM

$NKTX dead quiet but steadily climbing, I like this kind of move

2 · Reply

purplesniper Aug. 25 at 9:25 PM

$NKTX

0 · Reply

LSOTradingDesk Aug. 23 at 10:40 PM

$NKTX 👀

0 · Reply

Lukey63 Aug. 21 at 2:29 PM

$NKTX HOWL, a biotech with cash about equal to mkt value prior to today has doubled on the news that it is being used as a reverse merger with a private stage 3 biotech. NKTX and others like BOLT, ACRV and ACET are very attractive for the same given trading under cash value.

1 · Reply

OriginalTradeonrumor Aug. 19 at 8:44 PM

$NKTX good day! Pretty much XBI related so subject to dropping a bit when it goes down but hey it’s all good!!

0 · Reply

OriginalTradeonrumor Aug. 19 at 1:41 PM

$NKTX $XBI helping the cause today!

0 · Reply

OriginalTradeonrumor Aug. 12 at 1:44 PM

$NKTX as expected…so far so good!!!

0 · Reply

Nkarta price target lowered to $10 from $11 at Stifel

2026-08-11T10:10:37.000Z - 26 days ago

Nkarta price target lowered to $14 from $16 at H.C. Wainwright

2026-08-10T21:25:14.000Z - 27 days ago

Nkarta reports Q2 EPS (54c), consensus (36c)

Aug 10, 2026, 4:00 PM EDT - 27 days ago

Nkarta Earnings release: Q2 2026

Aug 10, 2026, 4:00 PM EDT - 27 days ago

Nkarta Quarterly report: Q2 2026

Jul 23, 2026, 1:30 AM EDT - 6 weeks ago

Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development

Jun 30, 2026, 2:00 PM EDT - 2 months ago

Nkarta Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Jun 26, 2026, 8:45 AM EDT - 2 months ago

Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

2026-06-23T11:33:17.000Z - 2 months ago

Nkarta initiated with a Buy at TD Cowen

Jun 10, 2026, 4:00 PM EDT - 2 months ago

Nkarta Transcript: AGM 2026

2026-05-18T12:43:42.000Z - 3 months ago

Nkarta price target lowered to $9 from $25 at Evercore ISI

2026-05-12T22:15:15.000Z - 3 months ago

Nkarta reports Q1 EPS (37c), consensus (37c)

May 12, 2026, 4:01 PM EDT - 3 months ago

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

May 12, 2026, 4:00 PM EDT - 3 months ago

Nkarta Earnings release: Q1 2026

May 12, 2026, 4:00 PM EDT - 3 months ago

Nkarta Quarterly report: Q1 2026

May 12, 2026, 4:00 PM EDT - 3 months ago

Nkarta Slides: Corporate presentation

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Nkarta Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Nkarta Proxy statement: Proxy filing

2026-04-15T20:05:13.000Z - 4 months ago

Nkarta announces agreement with FDA on changes to Ntrust-1, Ntrust-2 trials

Apr 15, 2026, 4:01 PM EDT - 4 months ago

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

Apr 15, 2026, 3:45 PM EDT - 4 months ago

Nkarta Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 7:00 AM EDT - 5 months ago

Nkarta to Participate in Needham Virtual Healthcare Conference

2026-03-31T11:08:50.000Z - 5 months ago

Nkarta price target lowered to $12 from $14 at Mizuho

2026-03-26T11:51:19.000Z - 5 months ago

Nkarta price target raised to $11 from $10 at Needham

2026-03-25T21:25:16.000Z - 5 months ago

Nkarta files $350M mixed securities shelf

2026-03-25T20:05:15.000Z - 5 months ago

Nkarta reports Q4 EPS (37c), consensus (29c)

Mar 25, 2026, 4:01 PM EDT - 5 months ago

Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights

Mar 25, 2026, 4:00 PM EDT - 5 months ago

Nkarta Annual report: Q4 2025

Mar 25, 2026, 4:00 PM EDT - 5 months ago

Nkarta Earnings release: Q4 2025

Mar 25, 2026, 4:00 PM EDT - 5 months ago

Nkarta Annual report: Q4 2025

Mar 25, 2026, 8:00 AM EDT - 5 months ago

Nkarta Registration statement: Registration filing

Mar 10, 2026, 10:40 AM EDT - 6 months ago

Nkarta Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 9:10 AM EST - 6 months ago

Nkarta Transcript: TD Cowen 46th Annual Health Care Conference

Feb 27, 2026, 8:00 AM EST - 6 months ago

Nkarta to Participate in March Investor Conferences

Dec 4, 2025, 10:50 AM EST - 9 months ago

Nkarta Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 7:09 AM EST - 9 months ago

Nkarta to Participate in Evercore Healthcare Conference

Nov 13, 2025, 5:00 PM EST - 9 months ago

Nkarta Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 10:40 AM EST - 9 months ago

Nkarta Transcript: Stifel 2025 Healthcare Conference

2025-11-11T12:45:27.000Z - 9 months ago

Nkarta price target lowered to $11 from $12 at Stifel

2025-11-10T21:05:10.000Z - 10 months ago

Nkarta reports Q3 EPS (29c), consensus (30c)

Nov 10, 2025, 4:01 PM EST - 10 months ago

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

Nov 10, 2025, 4:00 PM EST - 10 months ago

Nkarta Quarterly report: Q3 2025

Nov 10, 2025, 4:00 PM EST - 10 months ago

Nkarta Earnings release: Q3 2025

Nov 9, 2025, 6:00 PM EST - 10 months ago

Nkarta Slides: Corporate Presentation

Oct 30, 2025, 1:14 PM EDT - 10 months ago

Nkarta to Participate in November Investor Conferences

Oct 22, 2025, 10:07 AM EDT - 10 months ago

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

Sep 9, 2025, 8:30 AM EDT - 12 months ago

Nkarta Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:01 AM EDT - 1 year ago

Nkarta to Participate in a September Investor Conference

2025-08-14T11:21:16.000Z - 1 year ago

Nkarta price target lowered to $12 from $14 at Stifel

2025-08-12T20:13:01.000Z - 1 year ago

Nkarta reports Q2 EPS (31c), consensus (35c)

Aug 12, 2025, 4:01 PM EDT - 1 year ago

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Nkarta Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Nkarta Earnings release: Q2 2025

Jul 30, 2025, 11:00 AM EDT - 1 year ago

Nkarta Transcript: H.C. Wainwright “HCW@Home” Series

Jul 23, 2025, 8:01 AM EDT - 1 year ago

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

2025-06-10T10:55:13.000Z - 1 year ago

Nkarta price target lowered to $14 from $16 at Mizuho

2025-06-06T13:00:35.000Z - 1 year ago

Nkarta appoints Shawn Rose as CMO, head of R&D

Jun 6, 2025, 8:52 AM EDT - 1 year ago

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

2025-05-15T08:51:43.000Z - 1 year ago

Nkarta downgraded to Market Perform from Outperform at William Blair

2025-05-14T20:15:15.000Z - 1 year ago

Nkarta reports Q1 EPS (43c), consensus (45c)

May 14, 2025, 4:01 PM EDT - 1 year ago

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

May 14, 2025, 12:00 AM EDT - 1 year ago

Nkarta Quarterly report: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Nkarta Earnings release: Q1 2025

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Nkarta Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Nkarta Proxy statement: Proxy Filing

Apr 8, 2025, 11:00 AM EDT - 1 year ago

Nkarta Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:01 AM EDT - 1 year ago

Nkarta to Participate in an April Investor Conference

Mar 26, 2025, 4:01 PM EDT - 1 year ago

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Nkarta Earnings release: Q4 2024

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Nkarta Annual report: Q4 2024

Mar 10, 2025, 3:00 PM EDT - 1 year ago

Nkarta Transcript: Leerink Global Healthcare Conference 2025

Mar 3, 2025, 3:10 PM EST - 1 year ago

Nkarta Transcript: TD Cowen 45th Annual Healthcare Conference

Dec 5, 2024, 6:01 AM EST - 1 year ago

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Dec 4, 2024, 2:10 PM EST - 1 year ago

Nkarta Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 26, 2024, 7:02 AM EST - 1 year ago

Nkarta to Participate in an Upcoming Investor Conference

Nov 19, 2024, 10:55 AM EST - 1 year ago

Nkarta Transcript: Stifel 2024 Healthcare Conference

Nov 7, 2024, 4:02 PM EST - 1 year ago

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Nov 7, 2024, 4:00 PM EST - 1 year ago

Nkarta Earnings release: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Nkarta Quarterly report: Q3 2024

Sep 10, 2024, 12:30 PM EDT - 1 year ago

Nkarta Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 3, 2024, 4:01 PM EDT - 2 years ago

Nkarta to Participate in Upcoming Investor Conference

Aug 13, 2024, 9:03 PM EDT - 2 years ago

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Aug 13, 2024, 4:01 PM EDT - 2 years ago

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Nkarta Quarterly report: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Nkarta Earnings release: Q2 2024

Jul 24, 2024, 6:00 AM EDT - 2 years ago

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Jul 16, 2024, 6:01 AM EDT - 2 years ago

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

Jun 27, 2024, 6:00 AM EDT - 2 years ago

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Jun 13, 2024, 4:01 PM EDT - 2 years ago

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

May 9, 2024, 4:01 PM EDT - 2 years ago

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

May 9, 2024, 4:00 PM EDT - 2 years ago

Nkarta Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Nkarta Earnings release: Q1 2024

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Nkarta Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Nkarta Proxy statement: Proxy Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Nkarta Proxy statement: Proxy Filing

Apr 9, 2024, 1:30 PM EDT - 2 years ago

Nkarta Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 5, 2024, 3:35 PM EDT - 2 years ago

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 3, 2024, 4:02 PM EDT - 2 years ago

Nkarta to Participate in Upcoming Investor Conferences

Mar 26, 2024, 2:00 PM EDT - 2 years ago

Nkarta Transcript: H.C. Wainwright 2ND Annual Cell Therapy Virtual Conference

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Nkarta Slides: Corporate Presentation

Mar 25, 2024, 6:30 AM EDT - 2 years ago

Nkarta Announces Pricing of $240 Million Underwritten Offering

Mar 21, 2024, 4:01 PM EDT - 2 years ago

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Nkarta Earnings release: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Nkarta Annual report: Q4 2023

Mar 11, 2024, 12:00 PM EDT - 2 years ago

Nkarta Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 6, 2024, 9:10 AM EST - 2 years ago

Nkarta Transcript: TD Cowen 44th Annual Health Care Conference 2024

Dec 9, 2023, 8:31 PM EST - 2 years ago

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nov 28, 2023, 12:30 PM EST - 2 years ago

Nkarta Transcript: 6th Annual Evercore ISI HealthCONx Conference

Nov 9, 2023, 4:02 PM EST - 2 years ago

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

Nov 9, 2023, 4:00 PM EST - 2 years ago

Nkarta Quarterly report: Q3 2023

Nov 9, 2023, 4:00 PM EST - 2 years ago

Nkarta Earnings release: Q3 2023

Nov 7, 2023, 8:02 AM EST - 2 years ago

Nkarta to Participate at Upcoming Investor Conferences

Oct 17, 2023, 11:47 AM EDT - 2 years ago

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Nkarta Transcript: FDA Announcement

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Nkarta Press release: FDA Announcement

Oct 17, 2023, 7:01 AM EDT - 2 years ago

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Oct 16, 2023, 4:01 PM EDT - 2 years ago

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

Aug 18, 2023, 7:00 AM EDT - 3 years ago

Nkarta Quarterly report: Q2 2023

Aug 18, 2023, 7:00 AM EDT - 3 years ago

Nkarta Earnings release: Q2 2023

Aug 10, 2023, 7:01 AM EDT - 3 years ago

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

Aug 3, 2023, 8:02 AM EDT - 3 years ago

Nkarta to Participate at Upcoming Investor Conference

Jul 5, 2023, 4:02 PM EDT - 3 years ago

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

Jun 27, 2023, 8:00 AM EDT - 3 years ago

Nkarta Transcript: Study Update

Jun 27, 2023, 8:00 AM EDT - 3 years ago

Nkarta Press release: Study Update

Jun 27, 2023, 8:00 AM EDT - 3 years ago

Nkarta Slides: Study Update

$Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia$

Jun 27, 2023, 7:01 AM EDT - 3 years ago

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Jun 26, 2023, 4:01 PM EDT - 3 years ago

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program

Jun 10, 2023, 10:47 AM EDT - 3 years ago

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

May 11, 2023, 4:02 PM EDT - 3 years ago

Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

May 11, 2023, 4:01 PM EDT - 3 years ago

Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

May 11, 2023, 7:00 AM EDT - 3 years ago

Nkarta Quarterly report: Q1 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

Nkarta Earnings release: Q1 2023

Apr 26, 2023, 7:00 AM EDT - 3 years ago

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

TNYA

OriginalTradeonrumor Sep. 4 at 5:49 PM

$NKTX gobble gobble chomp chomp !! Another solid day!

0 · Reply

theBigDollarski Sep. 4 at 1:14 PM

$NKTX we get any good news on the trials and this will instantly double

0 · Reply

LSOTradingDesk Sep. 3 at 11:24 PM

$NKTX it's goin in this last hour of aftermarket 🏁

0 · Reply

aletz Aug. 27 at 7:03 PM

$NKTX dead quiet but steadily climbing, I like this kind of move

2 · Reply

purplesniper Aug. 25 at 9:25 PM

$NKTX

0 · Reply

LSOTradingDesk Aug. 23 at 10:40 PM

$NKTX 👀

0 · Reply

Lukey63 Aug. 21 at 2:29 PM

1 · Reply

OriginalTradeonrumor Aug. 19 at 8:44 PM

$NKTX good day! Pretty much XBI related so subject to dropping a bit when it goes down but hey it’s all good!!

0 · Reply

OriginalTradeonrumor Aug. 19 at 1:41 PM

$NKTX $XBI helping the cause today!

0 · Reply

OriginalTradeonrumor Aug. 12 at 1:44 PM

$NKTX as expected…so far so good!!!

0 · Reply

OriginalTradeonrumor Aug. 11 at 7:38 PM

$NKTX loved the dip today !!! Hoping folks took advantage

0 · Reply

youbi336 Aug. 11 at 4:34 PM

$NKTX This stock is such a piece of shit. Trades below cash and has potential with NKX-019 and still can't move except down. Even $FATE overtook it.

0 · Reply

Lukey63 Aug. 11 at 1:56 PM

$NKTX POS stock. This company better have some great news in the second half of the year. I am quite long, dead money for two years.

0 · Reply

Joesh82 Aug. 10 at 8:26 PM

$NKTX https://ir.nkartatx.com/static-files/2b3ff867-a641-4d99-b0d8-bf122aa4e5f1

0 · Reply

purplesniper Aug. 10 at 5:54 PM

$NKTX

0 · Reply

aletz Aug. 7 at 7:46 PM

$NKTX I like a quiet climb here. Phase 1 data imminent and phase 1s have tendency of showing primises and although the science it's not exactly the same but $ARTV has already shown strong potential and hopefully Nkarta can show it can be done without a need of mAbs. Holding both btw.

0 · Reply

OriginalTradeonrumor Aug. 7 at 7:12 PM

$NKTX started nibbling on this in the 2.30’s today ——earnings call next week will define the announcement date …$3+ prior to that date should happen

0 · Reply

ivocsev Aug. 6 at 7:16 PM

$NKTX seems promising long term

0 · Reply

Joesh82 Jul. 31 at 5:14 PM

$NKTX When you look at the chart it's fairly brutal and sentiment is bearish but nothing has actually changed. The company still has a strong cash position with the price trading below this and good management. We have upcoming data as a catalyst, potentially we could get an update on this at the upcoming earnings. This seems a great price to build a position.

0 · Reply

RaySan Jul. 31 at 2:12 PM

$NKTX Grabbed more @ $2.05

0 · Reply

Lukey63 Jul. 31 at 2:04 PM

$NKTX FFS! Where is the bottom in this POS?

0 · Reply

theBigDollarski Jul. 24 at 3:42 PM

$NKTX nabbed a couple thousand at 2.25....this stock is too easy

1 · Reply

Market Cap	209.15M
Revenue (ttm)	0.00
Net Income (ttm)	-104.08M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	447,400
Avg Vol	671,706
Day's Range	N/A - N/A
Shares Out	71.63M
Stochastic %K	97%
Beta	0.97
Analysts	Strong Sell
Price Target	$10.83